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 ANCA comes of age — but with 
caveats 
 Sally M.  Hamour 1 and  Alan D.  Salama 1 
 Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis are 
predominantly diseases of older patients, frequently involving the 
kidney. Bomback and colleagues studied disease outcome in very 
elderly patients (  >  80 years old) with ANCA-associated renal disease. 
Immunosuppression resulted in lower rates of end-stage renal disease 
at 1 year and lower mortality at 2 years. Although these data suggest 
we should treat these elderly patients with immunosuppression, 
the criteria for patient selection and the dosage and duration of the 
treatment regimen need to be established. 
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 Anti-neutrophil cytoplasmic  antibody 
(ANCA)-associated small-vessel vascu-
litides are predominantly diseases of older 
patients, frequently involving the kidney 
with focal necrotizing glomerulonephritis, 
and resulting in signifi cant morbidity and 
mortality. Th e majority of clinical trials 
investigating therapeutic regimens have 
recruited patients between 18 and 75 years 
old, leaving uncertainty regarding treat-
ment outcomes in those older patients for 
whom the risks of immunosuppressive 
treatment are frequently perceived to 
outweigh the benefits. Bomback and 
colleagues 1 (this issue) have performed 
a study to address disease outcome 
 specifi cally in very elderly patients (  >  80 
years old) with ANCA-associated renal 
disease. Th ey report that immunosuppres-
sion resulted in lower rates of end-stage 
renal disease (ESRD) at 1 year and lower 
morta lity at 2 years. So, on the basis of 
these data, should we be treating all our 
vasculitic patients with the same immuno-
suppressive protocols regardless of 
their age? 
 ANCA-associated vasculitis (AAV) 
constitutes a heterogeneous group of 
disorders with an incidence of around 
20 per million per year and a peak age of 
65 – 74 years. 2 In the elderly, AAV may 
present atypically or with vague constitu-
tional symptoms and can thus be diffi  cult 
to diagnose. A high index of clinical sus-
picion is required, evidenced by the fact 
that ANCA-associated pauci-immune 
glomerulonephritis is the most common 
fi nding in very elderly patients biopsied 
for acute kidney injury. 3 AAV may be life-
threatening, and, before the introduction 
of immunosuppressive treatment, morta-
lity was as high as 85 % at 1 year; this 
was radically transformed with the use of 
corticosteroids and alkylating agents. 4 
Even with modern treatment protocols, 
AAV results in considerable morbidity, 
with end-stage renal failure developing 
in 20 – 30 % of patients at 5 years, and 
significant mortality, with 18 and 24 % 
of patients dead by 1 and 5 years, respec-
tively. 5 Treatment is generally divided 
into more intensive induction therapy 
followed by long-term maintenance treat-
ment, but despite this, relapse rates are 
high, reaching almost 50 % over 5 years. 6 
 Treatment with immunosuppressive 
agents, such as cyclophosphamide and 
steroids, is associated with consider able 
side effects and cumulative toxicity, 
and a quarter of patients develop an 
adverse reaction during the fi rst year of 
treatment. 4 Little  et al. 7 have successfully 
teased out the relative importance of 
disease activity and treatment-related 
complications in contributing to early 
patient death. Prospective data from four 
European Vasculitis Study Group trials 
were used to compare the eff ects of vascu-
litis activity and adverse events on early 
mortality in 524 patients. One-year mor-
tality probability was 11.1 % , with 59 % 
of deaths attributable to adverse events 
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and only 19 % to active vasculitis. Th ere-
fore, the greatest threat to patients in their 
first year from diagnosis is treatment-
related rather than disease-related. Th is is 
especially true of older patients and those 
with kidney disease. A number of studies 
have confirmed that lower glomerular 
filtration rate and increasing age are 
independently associated with patient 
mortality. Harper and Savage 8 found that 
patients older than 65 had more severe 
renal involvement at presentation and 
were more likely to develop infections 
while receiving immunosuppression, with 
increased mortality. Th ose patients over 
65 were as likely to respond to treatment 
and just as likely to relapse as younger 
patients, suggesting the need for similar 
immunosuppressive regimens regardless 
of age, although dosing regimens were 
adjusted for increased age and decreased 
glomerular fi ltration rate. In another retro-
spective study, patients older than 65 
with vasculitis had higher rates of ESRD 
and a mortality rate of 60 % compared 
with 19 % in those under 65. 9 Finally, data 
from the combined European Vasculitis 
Study Group studies demonstrated that 
the combined burden of events (CBOE) 
score (an estimate of adverse events) 
strongly predicted 1-year mortality and 
was significantly influenced by both 
glomerular fi ltration rate and age. 7 Long-
term management of AAV therefore 
involves balancing the burden of immuno-
suppression with effective control of 
disease, and this balance is harder to 
achieve in older patients and those with 
renal impairment. 
 Bomback and colleagues 1 present a 
study of outcomes in very elderly 
AAV patients, more than 80 years 
old, with pauci-immune glomerulo-
nephritis on renal biopsy, and report that 
 immuno suppression reduced the risk of 
ESRD and death. Seventy-eight cases 
were identifi ed with a mean age of 83.3 
years and predominant myeloperoxidase-
ANCA positivity. Only 34 patients (44 % ) 
had extrarenal vasculitis manifestations, 
but, as might be expected, there were sig-
nificant comorbidities, including 19 % 
with diabetes mellitus, 25 % with cardiac 
disease, and 78 % with hypertension. 
 Data on 61 patients were available with 
regard to treatment; 50 patients were 
immunosuppressed, and 11 were not. 
Treatment was usually with a combina-
tion of steroids and oral cyclophospha-
mide, although, critically, the total doses 
prescribed were not known. Maintenance 
therapy was used in only 20 patients for a 
median of 6 months, again with no details 
regarding doses of drugs used. Moreover, 
the criteria physicians used in choosing 
to immunosuppress were unclear; how-
ever, half of the treated patients had extra-
renal disease, whereas all of the untreated 
group had renal-limited disease. In addi-
tion, the histological severity of glomeru-
lar injury was greater in those treated 
than in those not treated. Disease remis-
sion, defi ned by return of renal function 
to less than 1.5 times premorbid levels 
and no evidence of extrarenal disease, was 
not achieved in any of those not immuno-
suppressed and was attained in 49 % of 
those immunosuppressed. During follow-
up, infections were higher in the group 
treated with immunosuppression, but 
patients treated with immunosuppression 
of any duration had a signifi cantly lower 
rate of ESRD at 1 year compared with 
those not immunosuppressed (36.2 ver-
sus 72.7 % ). By 6 months 34 % of treated 
patients had died, and by a year 47 % had 
died, compared with 64 % of non-immuno-
suppressed patients. Overall, almost 70 % 
of patients reached a combined end point 
of ESRD or death within the fi rst year of 
diagnosis. Although there was no diff er-
ence in 1-year mortality, extending the 
follow-up period to 2 years did 
suggest a survival benefi t with immuno-
suppression. However, in considering this 
survival benefit, analysis was based on 
only 4 and 26 patients available beyond 
1 year in the non-immunosuppressed and 
immunosuppressed cohorts, respectively. 
 Relapse rates were low (4 % ) in the 
immunosuppressed and zero in the non-
immunosuppressed patients, during 
the variable follow-up period (1 week to 
67 months), unlike the rates reported in 
previous elderly AAV cohorts. In part, this 
may relate to the higher predominance 
of myeloperoxidase-ANCA, known to 
relapse less than proteinase 3-ANCA-
associated disease. 
 Th is study confi rms the high mortality 
of elderly patients with AAV and kidney 
disease and provides some insight into the 
outcomes of immunosuppression in the 
very elderly, suggesting benefi t from treat-
ing them, although there are a number of 
caveats. It is a retrospective analysis with 
an incomplete data set and a heterogene-
ous treatment group, in which the deci-
sion to immunosuppress was made 
according to undefined criteria. There 
may have been considerable bias in select-
ing those for immunosuppression, with 
the more frail elderly patients being per-
ceived as having the greatest likelihood of 
suff ering adverse events and thus omit-
ting immunosuppression. It supports the 
use of immunosuppression for renal and 
possibly for patient survival but cannot 
point us toward a particular treatment 
regimen. For the most part these patients 
were treated with cyclophosphamide and 
steroids. Adjustments are normally made 
in cyclophosphamide dose based on age 
and renal function, and it may be that 
those who survived treatment had a more 
modifi ed regimen than those who did 
not. Steroids, by contrast, are generally 
adjusted only for weight and remain a 
signifi cant potential culprit in promoting 
adverse events, as is evidenced by event 
rates in the recent rituximab / steroid 
trials. 10 In the future, increased use of 
biological treatments and the prospect 
of targeted immunotherapy may provide 
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 Figure 1  |  Numbers of patients with ANCA-associated vasculitis, followed in a large urban 
vasculitis clinic, according to age at presentation. The very elderly (  >  80 years) currently make 
up the smallest proportion of patients (3.3 % of 475 patients). 
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an improved side-effect profile in the 
elderly, although, disappointingly, 
the results of the two recent randomized 
rituximab studies have not suggested 
such a benefi t, in cohorts of older and 
younger patients. 10,11 
 Further prospective studies need to be 
conducted with older patients in order to 
guide treatment rationale in this group. 
Perhaps there should not be an upper age 
in future randomized studies, as the 
 elderly with renal failure are the group 
most likely to benefi t from novel regimens 
that attempt to reduce adverse eff ects. It 
should be noted that the very elderly 
(  >  80 years) constitute only a small per-
centage of the total AAV population 
 ( Figure 1 ), making up only 3.3 % of a large 
( n  =  475) urban cohort of patients, 
although this may be expected to increase 
in the future given the aging population. 
Th e high overall morbidity and mortality 
regardless of treatment provide a context 
within which decisions regarding immu-
nosuppression must be made. Specifi c 
questions relating to the type, intensity, 
and duration of immunosuppression 
need to be answered in order to optimize 
the risk – benefi t  balance. Furthermore, 
this cohort  demonstrated low relapse 
rates, accepting a variable follow-up 
period and  predominant myeloperoxi-
dase-ANCA positivity. Greater knowl-
edge about the risk and severity of relapse 
in the elderly, parti cularly those with 
ESRD, is crucial in determining the need 
for maintenance immuno suppression in 
those older patients. It is notable that 
despite all the controlled studies assessing 
induction and maintenance regimens, 
only one study (with recruiting recently 
completed and awaiting analysis) is 
assessing the dura tion of maintenance 
therapy requi red to maintain prolonged 
disease-free remission (see www.vasculitis.
org). With the increased incidence of 
immunosenescence in older patients, it 
may be that a more curtailed immuno-
suppressive regimen is suffi   cient to pro-
mote disease-free remission. 
 Th e study by Bomback  et al. 1 suggests 
that some form of immunosuppression is 
warranted in elderly AAV patients with 
kidney disease, to successfully prevent 
ESRD and patient demise, but we still do 
not know the precise details of what to 
give and for how long, so as to maximize 
treatment response, induce remission, and 
diminish life-threatening adverse events. 
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